GSK3B and uses thereof in the diagnostic and treatment of hypopigmentation disorders
US10632117B2 · kind B2 · utility
1Cited by
0References
1Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 16, 2015 |
| Grant date | Apr 28, 2020 |
| Priority date | — |
| Expiry date | Aug 27, 2036 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/207
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to the identification of the glycogen synthase kinase-3 beta (GSK3B or GSK-3P) as a therapeutic target of pigmentation disorder and as biomarker of pigmentation status. The invention in particular relates to products and methods for treating a hypopigmentation disorder. The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.